|
|
|
21.03.26 - 15:18
|
Domestic companies launch semaglutide jabs at affordable prices (Times of India)
|
|
|
Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis....
|
|
|
|
|
03.02.26 - 18:48
|
India-US trade deal clarity: Pharma exporters gain edge in US; sector eyes growth boost (Times of India)
|
|
|
Indian drugmakers anticipate significant benefits from the proposed India-US trade agreement, offering much-needed clarity and stability for the lucrative US pharmaceutical market. This development is expected to boost expansion plans and growth prospects for major companies like Sun Pharma and Dr. Reddy's, enhancing their competitive edge and strengthening India's role in global supply chains....
|
|
|
|
|
30.01.26 - 14:03
|
Coya Therapeutics Announces $11.1 Million Private Placement (Business Wire)
|
|
|
- Dr. Reddy's Laboratories, Inc., a subsidiary of Coya's current strategic collaborator, makes a $10 million investment
- Greenlight Capital, Coya's largest institutional shareholder, is the only other investor participating in the offeringHOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, 2026, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy's Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Comp...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.12.25 - 23:36
|
Reddys to buy out IHCL′s stake in Taj GVK Hotels (Times of India)
|
|
|
GVK Reddy's daughter, Shalini Bhupal, is set to acquire Indian Hotels' 25.5% stake in Taj GVK Hotels & Resorts for Rs 592 crore, becoming the largest shareholder. This move increases the GVK Reddy family's stake to approximately 75%, while Indian Hotels will continue to manage the hotel portfolio under long-term contracts....
|
|
|
|
|
|
|
|
|
05.12.25 - 04:24
|
JSW Steel, Kotak Mahindra & more: Top stocks to buy today — Check list (Times of India)
|
|
|
Brokerage firms are bullish on JSW Steel and Tata Consumer Products, forecasting significant growth. Aurobindo Pharma shows strong momentum. Kotak Mahindra Bank might acquire IDBI Bank, a move that could boost earnings. Dr Reddy's Labs is on track for key biosimilar launches and will focus on brand acquisitions. These insights offer a glimpse into potential market movements....
|
|
|
|
|
|
|
03.12.25 - 03:18
|
Dr Reddys, Titan & more: Top stocks to buy on December 3 — Check list (Times of India)
|
|
|
Leading financial institutions are bullish on select Indian stocks. HSBC recommends Dr Reddy's Labs for its semaglutide prospects, while Goldman Sachs sees strong growth for Titan's jewellery and other ventures. Bernstein is optimistic about Trent's recovery, and CLSA highlights Power Grid Corp's strategic entry into battery storage. ITC faces potential tax uncertainty....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
